Novo Nordisk is a healthcare company that focuses on diabetes care. Its diabetes product portfolio includes new generation insulin, a full portfolio of modern insulin and human insulin, and a portfolio of GLP-1 receptor agonists administered through subcutaneous injection and as a tablet. Novo Nordisk’s marketed portfolio includes haemophilia and growth hormone therapies. The company carries out the discovery, development, manufacturing, and marketing of pharmaceutical products through two business segments – Diabetes and Obesity care and Biopharm. It produces active pharmaceutical ingredients (APIs) for glucagon and growth hormone therapy, products for hormone replacement therapy, oral treatment of diabetes, and durable devices.
Novo Nordisk’s research and development (R&D) division focuses on therapeutic proteins for diabetes, obesity, haemophilia, growth disorders, and other serious chronic diseases such as NASH (non-alcoholic steatohepatitis), cardiovascular diseases, chronic kidney disease, and Alzheimer’s. Some of the company’s compounds that are in Phase 3 development or have recently been filed for regulatory approval are Macimorelin (EX2020), Mim8 (NN7769), Insulin Icodec (NN1436), and Semaglutide (oral) 50 mg.